T. Rowe Price Investment Management Inc. Invests $78.11 Million in HealthEquity, Inc. (NASDAQ:HQY)

T. Rowe Price Investment Management Inc. purchased a new stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 814,034 shares of the company's stock, valued at approximately $78,107,000. T. Rowe Price Investment Management Inc. owned about 0.94% of HealthEquity at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Arcadia Investment Management Corp MI bought a new position in HealthEquity in the 4th quarter worth about $26,000. Transce3nd LLC bought a new position in HealthEquity in the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC boosted its stake in HealthEquity by 34.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 384 shares of the company's stock worth $37,000 after purchasing an additional 98 shares during the period. Proficio Capital Partners LLC bought a new position in HealthEquity in the 4th quarter worth approximately $39,000. Finally, UMB Bank n.a. boosted its stake in HealthEquity by 65.6% in the 4th quarter. UMB Bank n.a. now owns 414 shares of the company's stock worth $40,000 after purchasing an additional 164 shares during the period. Institutional investors own 99.55% of the company's stock.

HealthEquity Trading Up 1.6 %

HQY stock traded up $1.39 during mid-day trading on Thursday, reaching $87.11. The company had a trading volume of 239,989 shares, compared to its average volume of 773,589. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. The firm has a 50 day moving average of $90.32 and a 200 day moving average of $96.43. HealthEquity, Inc. has a 12 month low of $65.01 and a 12 month high of $115.59. The company has a market capitalization of $7.53 billion, a PE ratio of 80.01, a price-to-earnings-growth ratio of 1.60 and a beta of 0.49.

Insider Activity at HealthEquity

In other news, Director Robert W. Selander sold 5,750 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total value of $446,487.50. Following the completion of the transaction, the director now owns 84,969 shares of the company's stock, valued at $6,597,842.85. The trade was a 6.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Henry Fiore sold 8,881 shares of the business's stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the transaction, the executive vice president now directly owns 56,655 shares of the company's stock, valued at approximately $4,433,820.30. This trade represents a 13.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,381 shares of company stock valued at $1,781,432 over the last 90 days. Insiders own 2.20% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Raymond James raised shares of HealthEquity from an "outperform" rating to a "strong-buy" rating and dropped their price objective for the stock from $120.00 to $115.00 in a research note on Tuesday, March 25th. Wells Fargo & Company boosted their target price on shares of HealthEquity from $110.00 to $125.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. KeyCorp reduced their target price on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th. Barrington Research restated an "outperform" rating and issued a $112.00 target price on shares of HealthEquity in a report on Friday, April 11th. Finally, The Goldman Sachs Group reduced their target price on shares of HealthEquity from $107.00 to $94.00 and set a "neutral" rating on the stock in a report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, HealthEquity presently has a consensus rating of "Buy" and an average target price of $111.75.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.